on the subject, had not made significant changes in her behavior.
The patient was placed on the Dexcom Seven Plus (San Diego, Calif.) continuous glucose monitoring (CGM) system for 7 days and was instructed on its use by a certified diabetes educator. She required assistance from her husband in calibrating the CGM. She was taught to audibly recognize high blood glucose alerts (set at 180 mg/dl) by a double-beep from the CGM device and low blood glucose alerts (set at 80 mg/dl) by a triple-beep from the monitor. M.P. was able to quickly learn after a few days that she frequently fluctuated rapidly between hyperglycemia alarms and hypoglycemia alarms and was likely giving herself an overly aggressive correction dose of insulin when her glucose was high and eating too much when it was low. The patient made appropriate changes on her own and was able to improve her average blood glucose from 162 mg/dl during the first 4 days of CGM use to 138 mg/dl during the next 4 days. Her glucose variability improved, as measured by a decrease in the standard deviation from ± 61 to ± 39 mg/dl. The percentage of time spent in the high glucose range (> 180 mg/dl) improved from 35 to 18%, and the percentage of time spent in the low glucose range (< 80 mg/dl) improved from 9 to 3% with no episodes of severe hypoglycemia (Figures 1 and 2) . This case report clearly demonstrates the utility of CGM technology in elderly or visually impaired patients with diabetes, as evidenced by significant improvements in glycemic control, glucose variability, and patient safety in a short period of time. This is a population of patients that has most likely been thought to lack the ability to benefit from CGM technology, and this case report disproves this myth. With proper patient training, the use of CGM technology in the elderly or visually impaired population should not be discouraged. 
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